Anne O’Riordan
Jazz PharmaceuticalsAbout Anne O’Riordan
Anne O’Riordan, age 57, has served as an independent director of Jazz Pharmaceuticals since February 2019 (Class III; current term expires in 2026). She brings 30 years of leadership advising life sciences and healthcare companies globally, including senior roles at Accenture culminating as Global Industry Senior Managing Director for Life Sciences, and recent experience as Group Director and board member at Jardine Matheson Limited with board service at portfolio companies; she holds a B.Sc. in Biotechnology from Dublin City University and a postgraduate diploma in Financial Accounting and MIS from the University of Galway .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Accenture (formerly Andersen Consulting) | Life Sciences practice; Global Industry Senior Managing Director for Life Sciences | 29 years prior to 2019 | Led global growth and management of Life Sciences across geographies; digital and innovation strategy leadership |
| Jardine Matheson Limited | Group Director and Board Director | Jun 2019 – Dec 2024 | Strategic oversight across multiple industry segments in North and Southeast Asia |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Livi Bank Limited (privately-held) | Director | Current | Digital bank based in Hong Kong |
| Mandarin Oriental Hotel Group International Limited | Director | During Jardine tenure | Portfolio company board service |
| Hong Kong Land Limited | Director | During Jardine tenure | Portfolio company board service |
| Dairy Farm Management Services Limited | Director | During Jardine tenure | Portfolio company board service |
| American Chamber of Commerce in Hong Kong | Board of Governors | 2019–2024 | Governance and business community leadership |
| International Women’s Forum of Hong Kong | Board | 2021–2023 | Non-profit leadership |
| University of Galway, J.E. Cairns Business School | Advisory Board | 2022–present | Academic advisory engagement |
| The Women’s Foundation; 30% Club | Member | Ongoing | Diversity and inclusion advocacy |
Board Governance
- Committee assignments: Audit Committee (member); Compensation and Management Development Committee (member). She rotated off the Nominating Committee in 2024 as part of committee refreshment .
- Committee chairs: None; Audit chaired by Patrick Kennedy; Compensation chaired by Jennifer E. Cook .
- Independence: Listed as an independent director; all members of Audit and Compensation Committees meet Nasdaq/SEC independence requirements, with the Board affirming no relationships impairing Compensation Committee members’ independence .
- Attendance/engagement: The Board met 10 times in 2024; each director attended at least 75% of Board and applicable committee meetings, and all 12 directors attended the 2024 AGM; independent directors held executive sessions at each regular Board meeting .
- Committee activity: Audit Committee held 4 meetings in 2024; Compensation Committee held 5 meetings in 2024 .
Fixed Compensation
| Fiscal Year | Fees Earned (Cash, USD) | Notes |
|---|---|---|
| 2024 | $101,087 | Paid in Euros with USD conversion via quarterly OANDA rates; cash fees comprise $75,000 Board retainer plus applicable committee retainers |
Director compensation policy (cash schedule):
| Position | Annual Cash Compensation |
|---|---|
| Independent Director (Board retainer) | $75,000 |
| Lead Independent Director (additional) | $50,000 |
| Audit Committee Member | $15,000 |
| Audit Committee Chair (additional) | $25,000 |
| Compensation Committee Member | $12,500 |
| Compensation Committee Chair (additional) | $25,000 (raised from $22,500 on Apr 25, 2024) |
| Nominating Committee Member | $10,000 |
| Nominating Committee Chair (additional) | $20,000 |
| SMC Member | $12,500 |
| SMC Chair (additional) | $25,000 (raised from $22,500 on Apr 25, 2024) |
| Transaction Committee Member | $2,500 per meeting (up to $10,000) |
| Transaction Committee Chair | $5,000 per meeting (up to $20,000/year) |
Performance Compensation
| Equity Component | Grant Date | Shares/Units | Grant Date Fair Value (USD) | Vesting/Terms |
|---|---|---|---|---|
| Annual RSU grant (non-employee director) | Aug 2, 2024 | 3,731 RSUs | $422,573 | Time-based; annual director RSUs vest in full on the first anniversary of the AGM; if a director resigns/does not stand for re-election at term end, unvested annual grant vests at the AGM effective date |
| Director RSU target policy | AGM date annually | Target value: $400,000 | Value converted to shares using 30-day average share price ending on grant date | Automatic grants for continuing/elected directors; prorated for mid-year appointments |
Additional compensation policy notes:
- Aggregate cap: Total director compensation per AGM-to-AGM year capped at $750,000; $1,350,000 for first-year appointees .
- Travel/education: Reimbursement for travel and director/healthcare education programs; no Irish tax equalization payments for reimbursements in 2024 .
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public company boards | None |
| Current private company boards | Livi Bank Limited (Hong Kong, digital bank) |
| Prior external boards | Jardine Matheson Limited; Mandarin Oriental Hotel Group International Limited; Hong Kong Land Limited; Dairy Farm Management Services Limited |
| Independence and related-party review | Audit Committee oversees related-person transactions; Board affirmed independence for Audit and Compensation Committee members |
Expertise & Qualifications
- 30 years advising life sciences and healthcare companies across geographies; leader in digital and innovation strategy .
- Senior operating experience in global consulting (Accenture Life Sciences) and Asian conglomerates (Jardine Matheson) .
- Education: B.Sc. Biotechnology (Dublin City University); postgraduate diploma in Financial Accounting and MIS (University of Galway) .
- Governance/d&I involvement: American Chamber of Commerce Hong Kong (2019–2024); International Women’s Forum Hong Kong (2021–2023); University of Galway advisory board (2022–present); member of The Women’s Foundation and the 30% Club .
Equity Ownership
| As-of Date | Beneficially Owned Shares (#) | % of Shares Outstanding | Notes |
|---|---|---|---|
| May 12, 2025 | 29,737 | <1% (asterisk in table) | Footnote indicates 18,670 shares via options exercisable within 60 days |
| Dec 31, 2024 (award inventory) | 18,670 options outstanding; 3,731 RSUs outstanding | — | Option/RSU counts per director inventory table |
Ownership alignment policies:
- Director ownership guideline: 5x annual cash retainer within five years; as of April 1, 2025, all non-employee directors were in compliance except Mr. Kennedy (joined Mar 2024) and Ms. Hamill (joined Jul 2024) .
- Anti-hedging/pledging: Insider trading policy prohibits directors from hedging or pledging Company securities .
Governance Assessment
-
Board effectiveness: Dual service on Audit and Compensation Committees positions O’Riordan at the core of financial oversight and human capital/compensation governance; Audit (4 meetings) and Compensation (5 meetings) activity levels support engagement .
-
Independence and attendance: Listed independent; Board and committee independence confirmed; Board met 10 times; directors met AGM attendance and minimum 75% meeting thresholds; independent director executive sessions at each regular meeting enhance oversight quality .
-
Compensation mix and alignment: 2024 director pay for O’Riordan weighted to equity via annual RSU ($422,573) versus cash fees ($101,087), consistent with policy targeting $400,000 RSU grants and robust ownership guidelines (5x retainer) with compliance noted as of April 1, 2025 .
-
Conflicts and related-party exposure: Audit Committee explicitly oversees related-person transactions; Compensation Committee independence affirmed with no relationships impairing judgment; insider policy bans hedging/pledging, and no 2024 tax equalization reimbursements occurred—reducing common governance red flags .
-
RED FLAGS: None disclosed specific to O’Riordan (no related-party transactions or pledging reported; independence affirmed for relevant committees) .